Curavit

A trial running right now, with nobody in the building

Somewhere in the United States, a woman is filling out a multi-day symptom diary on her phone for a clinical trial she enrolled in from her kitchen. She has never met a study coordinator in person. She has never driven to a research site. There is no research site - not in the way medicine has meant that word for a century. Her trial is being run by Curavit, and the site she belongs to has an address in the cloud.

That trial - the APPROVE study, testing a prescription digital therapeutic for overactive bladder - hit its recruitment target two months ahead of a six-month deadline. Curavit enrolled 298 of the 596 participants and opened exactly zero physical locations to do it. For a company whose entire premise is that the building was always the bottleneck, that is the whole argument in one data point.

The science was never the slow part

Here is the open secret of drug development: the molecule usually works long before the trial does. What stalls a study is mundane and human - finding enough of the right patients, getting them enrolled, keeping them in, and collecting clean data without losing half of it to missed appointments and three-hour commutes. Roughly four in five trials miss their enrollment timelines. Every missed month is burned money and delayed medicine.

The traditional fix was to add more sites - more buildings, more staff, more coordinators chasing more paperwork. It is a strategy with a certain charm, in that it solves a logistics problem by manufacturing more logistics. Curavit looked at that and asked a quieter question: what if the patient never had to travel at all?

This problem sharpened with a new kind of medicine. Digital therapeutics - software you are prescribed, the way you would be prescribed a pill - need clinical proof just like drugs do. But running an app's trial through brick-and-mortar sites is a strange mismatch: a digital product evaluated through analog infrastructure. The medium and the method had stopped agreeing.

Three veterans bet the site was optional

Curavit was founded in 2020 by three people who had each spent roughly three decades at the intersection of technology and clinical research - which is to say, they were not tourists. CEO Joel Morse had previously built C3i, a tech-enabled clinical-trial services company whose client list ran through Medidata, Quintiles, and Merck. Co-founder and Chief Medical Officer Dr. Pam Diamond spent more than 30 years as a Harvard-affiliated head and neck surgeon. Co-founder Dave Hanaman rounded out the commercial side as President and Chief Commercial Officer.

Their bet was specific and, at the time, slightly heretical: a clinical site does not have to be a place. It can be a software platform plus a remote team that recruits, consents, monitors, and collects data wherever the patient already is. Keep the scientific and regulatory rigor; throw out the real estate.

A clinical site you log into

Curavit calls itself "The Innovation CRO," but the heart of the company is the Virtual Clinical Site - a fully integrated, decentralized site that does everything a physical one does, minus the waiting room. It runs on STRATUS, Curavit's platform for digital recruitment, electronic consent, remote monitoring, and ePRO/eCOA data capture. Patients participate from home; coordinators work remotely; the data lands clean.

Crucially, Curavit does not demand you tear up your existing trial to use it. It can run the whole study, run one function (as a Functional Service Provider), or sit beside your current CRO and physical sites as the virtual piece that handles the part where enrollment usually stalls. It is less a rival to the old model than a patch for its worst bug.

The numbers that make skeptics pause

A virtual site is a lovely idea right up until someone asks whether it actually enrolls patients faster. So here is the receipt. The APPROVE trial gave Curavit a tidy 596-patient yardstick to recruit against, on a six-month clock. The chart below is the part that matters.

Half the entire trial's participants, recruited by a site with no physical address, finishing a third faster than required. And APPROVE was not a one-off: Curavit also completed a fully virtual trial for Sana Health's investigational PTSD therapeutic, and its client roster includes Amara Therapeutics, Lark Health, MedRhythms, Swing Therapeutics, and Beach Tree Labs.

Wherever they live, work, or study

Strip away the platform names and the funding rounds, and Curavit's mission is about who gets to be in a trial at all. Traditional sites cluster near major research hospitals, which quietly selects for patients who live nearby, can take time off, and own a reliable car. That is not a representative sample of anyone's disease. By recruiting remotely, a virtual site can reach more diverse patient populations - the people the old model kept accidentally filtering out.

For digital therapeutics, the mission has a second edge. These products only matter if they reach patients, and they only reach patients if payers cover them. Curavit's HEOR practice exists to generate the health-economics evidence that turns a cleared app into a reimbursed one - closing the gap between "FDA says it works" and "your plan will pay for it."

The building was always the assumption

Decentralized trials are no longer a fringe experiment - regulators, sponsors, and alliances now treat them as part of the toolkit, and AI-driven recruitment and remote monitoring keep lowering the cost of running them. Curavit's wager is that the physical site goes from default to option: used when the science demands it, skipped when it is just inertia. If that holds, the company that learned to run trials without a front door has a head start on the version of the industry everyone else is migrating toward.

Back to that woman with the symptom diary on her phone. A decade ago, her trial either happened in a research hospital she may not live near, or it did not happen with her in it at all. Curavit's whole reason for existing is that there is now a third option - the trial finds her. The site she belongs to has no waiting room, no parking lot, and no front door. That used to be a problem. Curavit decided it was the point.